[1] The dramatic decline issue. ART should probably be started within this range in annual AIDS-related mortality has largely been depending on the symptoms, viral load, CD4 slope, attributed to the use of highly active antiretroviral patient preference, and associated co-morbidities. therapy (HAART). Several effective antiretroviral agents are available and many more are in the pipeline
The pretreatment evaluation should include a [ Table 1 ]. However, injudicious use of ART may be complete history and physical examination, fundus harmful to patients as well as society at large. It is examination, complete blood count, biochemistry therefore essential that the treating physician has a profile, lipid profile, CD4/CD8 T cell count/ratio, clear set of goals to guide him/her. This includes plasma HIV-1 RNA measurement (viral load) and achieving not just maximal viral load suppression or supplementary tests including VDRL, Mantoux test, qualitative and quantitative immune reconstitution chest X-ray and serology for hepatitis C and B. [3] In
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all the above investigations, so a judicious decision Moreover, all this needs to be done through rational is required. The supplementary tests are done if sequencing of drugs in a fashion that achieves the there is suspicion of underlying opportunistic above mentioned clinical, virologic, and immunologic infections so as to treat them before starting ART as goals while maintaining treatment options, limiting also to predict possible immune reconstitution drug toxicity and facilitating adherence.
inflammatory syndrome (IRIS).
INITIATING ART
[2]
This decision should be based on CD4 cell count, symptoms, and viral load. The CD4 count is the most important indicator for initiating treatment according to guidelines, and all agree that treatment is indicated for all patients with a CD4 count < 200 cells/mm 3 . Symptomatic HIV infection is an indication for ART,
ADHERENCE TO ART
Before starting ART, it is imperative that the patient has a fair idea that therapy is long-term i.e., life-long; and that compliance with the drug regimen is most important for good virologic response. At least 95% adherence is required for durable and optimal viral suppression. Strategies to improve adherence have 
Atazanavir ( been adequately detailed elsewhere. [4] serum levels due to enzyme induction by rifampicin. However, these regimens are extremely effective and
FIRST-LINE REGIMENS
enable the clinician to reserve PIs for second-line regimens. A second advantage is the availability of The initial regimen is the most important regimen fixed drug combinations of these molecules, which because it is associated with the greatest probability lead to enhanced patient compliance and adherence. of achieving prolonged viral suppression. In resourceFactors that influence the probability of prolonged limited settings like ours, nucleoside analogs reverse viral suppression with any regimen include potency, transcriptase inhibitors (NRTI) / non-nucleoside analogs adherence, baseline viral load, viral load nadir and reverse transcriptase inhibitors (NNRTI) triple rapidity of viral load response. Prior exposure to combinations form the backbone of ART [5] [ Figure 1 ]. antiretroviral agents may also affect the response. Cost is an important determinant of this decision, as are host factors such as pregnancy, tuberculosis (TB),
ART DRUG TOXICIT Y
Hepatitis B/C virus (HBV/HCV) co-infection, and HIV-2 infection. A 3TC-containing regime is preferred in HBV
The major class toxicities of NRTIs are bone marrow co-infection, while EFV is the preferred molecule in suppression and mitochondrial toxicity (lactic acidosis, TB, albeit at a higher dose to compensate for the low steatohepatitis, peripheral neuropathy, insulin resistance and lipodystrophy). While NNRTIs are associated with skin rash and hepatitis, PIs cause gastrointestinal intolerance and lipid metabolism anomalies. The major individual toxicities include DURG INTERACTIONS: [3, 6] NNRTIs, except DLV, are cytochrome P450 3A4 (CYP3A4) inducers while PIs (except TPV) are enzyme inhibitors; the result is a plethora of drug interactions. etc. Several detailed commentaries on drug interactions of ART are available. [7] [8] [9] [10] the second-line regimen.
TREATMENT FAILURE HIV-2 INFECTION
Treatment failure is defined using the same variables There are certain genomic differences between HIV-1 that define the goals of antiretroviral therapy. Virologic and -2, which preclude the use of NNRTIs in treatment. failure is viral load (VL) > 200 c/mL or a sustained VL However, NRTIs are as effective as in HIV-1, but the > 50 c/mL, after 24 weeks of therapy. Immunologic efficacy of PI is variable. IDV may be less active against failure is arbitrarily defined as failure of the CD4 count HIV-2, while SQV, RTV, LPV /r and NFV appear to have to rise by 25-50 cells/mm 3 in the first year after HAART. comparable activity. These issues should be kept in Clinical failure is defined as the occurrence of an AIDSmind before deciding any regime for HIV-2 infection. defining opportunistic complication after three months of HAART, when immune reconstitution inflammatory NEED FOR A LONG-TERM VIEW syndrome (IRIS) has been excluded.
To conclude, ART provides a lifeline to those infected Causes of treatment failure are many. They include by the virus. Judicious use of these drugs is essential non-adherance or partial adherence, subtherapeutic to ensure delayed development of resistance, and drug levels, wrong choice of ART and selection of durable viral suppression. It is essential to define mutant strains leading to drug resistance. treatment goals prior to starting ART in the HIV infected and to select the most appropriate tools to SECOND-LINE REGIMENS [11, 12] achieve these goals [ Table 2 ]. often not been chosen with long-term treatment as the first priority. It is now time to take a different view, especially in settings where, in the foreseeable future, drug options will still be limited. It is mandatory to make the right choices from the very beginning of treatment. An initial choice of the cheapest combination will come at a high cost later on. Although price considerations remain important, regimen choices should be driven mainly by data demonstrating durability of therapy, which is
